Key Highlights
- Kite evaluates Cellares’ automated Cell Shuttle platform.
- Proof-of-concept evaluation to assess future manufacturing viability.
- Potential to enhance CAR T-cell therapy manufacturing capabilities.
Source: Business Wire
Notable Quotes
- “Given that manufacturing is central to how we deliver CAR T-cell therapies to physicians and patients, we are always assessing what technologies could further enhance our best-in-class manufacturing capabilities.” — Chris McDonald, Senior Vice President and Global Head of Technical Operations at Kite
- “This agreement with Kite allows the unique capabilities of our Cell Shuttle platform to be potentially utilized by Kite in the future, and reinforces Cellares’ position as a cell therapy manufacturer with advanced automated technology.” — Fabian Gerlinghaus, CEO and Co-Founder at Cellares
SoHC's Take
The collaboration between Kite and Cellares represents a significant step forward in the automation of cell therapy manufacturing. The Cell Shuttle platform’s potential to streamline and enhance the production of CAR T-cell therapies could revolutionize the industry, offering scalable, cost-effective solutions to meet growing global demand. By integrating such advanced technologies, Cellares not only positions itself as a leader in the field but also sets a new standard for manufacturing efficiency and reliability in cell therapy production. This partnership underscores the critical role of innovation in advancing healthcare and delivering life-saving treatments to patients worldwide.
